UroGen Pharma Stock Forecast
NASDAQ: URGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 36.83 0.00%
URGN analyst consensus
Consensus (8 analysts)
strong_buy
Avg. price target
$60.00+62.91%
- Strong buy 1
- Buy 6
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 8 Wall Street analysts covering UroGen Pharma (2026-10-08), 7 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $60.00, with a high estimate of $75.00 and a low estimate of $48.00. The average target implies upside of 62.9% from the current price of $36.83.
The spread between the highest and lowest targets is 56.3%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for URGN.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 13% |
| Buy | 6 | 75% |
| Hold | 1 | 13% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $48.00 | +30.33% |
| Average target | $60.00 | +62.91% |
| High target | $75.00 | +103.64% |